Here are the latest developments on pancreatic cancer, based on recent reputable sources:
-
FDA expanded access and new approvals in 2026:
- The FDA announced expanded access for daraxonrasib, a targeted therapy, for patients with metastatic pancreatic cancer, reflecting a potential extension of survival in a subset of patients [pancreatic cancer news sources, 2026]. This aligns with ongoing efforts to bring novel agents to patients outside of traditional trial settings [PanCAN News, 2026].
- A separate FDA approval in 2026 authorized a wearable device used in combination with chemotherapy for locally advanced pancreatic cancer, representing a new multimodal approach being evaluated to improve outcomes [PanCAN News, 2026].
-
Survival and detection context:
- Pancreatic cancer mortality remains high with five-year survival around the low teens, underscoring the need for early detection and better treatments; multiple organizations have called for increased investment in research and early detection initiatives in response to stagnant survival metrics [PanCAN News, 2026; Pancreatic Cancer Action Network statements, 2025–2026].
- AI-assisted early detection research is progressing, with studies showing potential to detect pancreatic cancer earlier than current methods, though such tools are not yet standard-of-care and require further validation [Mayo Clinic AI studies; related news reports, 2026].
-
Neuroendocrine and other pancreatic cancer subtypes:
- FDA approvals in 2024–2025 for targeted therapies specific to pancreatic neuroendocrine tumors (PNETs) indicate continued expansion of treatment options for distinct pancreatic cancer subtypes beyond pancreatic ductal adenocarcinoma (PDAC) [FDA press releases, 2024–2025; PanCAN News, 2025].
-
Notable research and funding updates:
- PanCAN and other foundations reported continued investment in research grants aimed at accelerating early detection and novel treatments, highlighting a sector-wide push despite challenges in federal funding [PanCAN press releases, 2024–2025].
If you’d like, I can:
- Pull the most recent articles and summarize key clinical trial results with dates and patient impact.
- Create a short timeline of major FDA approvals and research milestones in 2024–2026.
- Compile a brief overview tailored to your location (Dallas, TX) with local resources and patient support groups.
Would you prefer a focused summary on clinical trials, regulatory updates, or patient support resources? I can also provide a concise list of sources with direct links.
Sources
For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer. For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer. For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer. CBS News New York's Carolyn Gusoff reports. Around 3,000 people gathered at...
www.cbsnews.comPancreatic Cancer Latest News and Stories - Pancreatic Cancer Action Network
pancan.orgA recent study published in Nature Communications, sponsored by the UCLA Health Jonsson Comprehensive Cancer Center, showed that adding immunotherapy to standard chemotherapy, before surgery, may benefit a subset of […] The Hirshberg Foundation for Pancreatic Cancer Research is proud to announce the launch of the PNET Pathway Grant Program, a new research initiative focused on accelerating discoveries in pancreatic neuroendocrine […]
pancreatic.orgRead about the latest medical research concerning pancreatic cancer and other disorders of the pancreas. Consider new treatment options.
www.sciencedaily.comRead the latest about Pancreatic Cancer North America's awareness efforts, creative partnerships and organizational news.
pancreaticcancerna.org